Compare KFY & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFY | ADMA |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 1998 | 2012 |
| Metric | KFY | ADMA |
|---|---|---|
| Price | $62.91 | $13.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $71.33 | $32.00 |
| AVG Volume (30 Days) | 532.8K | ★ 3.6M |
| Earning Date | 03-09-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.11% | N/A |
| EPS Growth | ★ 42.41 | N/A |
| EPS | ★ 3.84 | 0.60 |
| Revenue | ★ $1,819,519,000.00 | $42,219,783.00 |
| Revenue This Year | $7.14 | $27.46 |
| Revenue Next Year | $3.32 | $22.11 |
| P/E Ratio | ★ $16.13 | $24.02 |
| Revenue Growth | 12.20 | ★ 43.85 |
| 52 Week Low | $58.27 | $13.76 |
| 52 Week High | $78.50 | $25.67 |
| Indicator | KFY | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 33.35 |
| Support Level | $62.46 | N/A |
| Resistance Level | $64.35 | $16.87 |
| Average True Range (ATR) | 1.79 | 0.73 |
| MACD | 0.19 | -0.13 |
| Stochastic Oscillator | 68.02 | 0.62 |
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.